Propanc Biopharma (PPCB) Stock Price, News & Analysis

Company Overview

Propanc Biopharma Ltd. (OTCMKTS:PPCB) is a clinical‐stage biotechnology company focused on developing novel proenzyme‐based therapeutics for the treatment of pancreatic cancer and other solid tumors.

The company’s lead candidate, PRP, combines recombinant proteases designed to disrupt tumor stroma and enhance the efficacy of standard chemotherapies, aiming to improve patient outcomes and quality of life.

Propanc also continues to advance its pipeline by exploring additional proenzyme formulations and delivery methods to address unmet medical needs across various oncology indications.

Key Stats

• Today's Range: $6.60 to $6.60
• 50-Day Range: $1.99 to $8.00
• 52-Week Range: $1.25 to $145.46
• Volume: 538 shs
• Average Volume: 1,774 shs
• Market Capitalization: $132 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PPCB Stock Analysis - Frequently Asked Questions

How have PPCB shares performed this year?

Propanc Biopharma's stock was trading at $0.0002 at the beginning of 2025. Since then, PPCB shares have increased by 3,299,900.0% and is now trading at $6.60.

How were Propanc Biopharma's earnings last quarter?

Propanc Biopharma Inc (OTCMKTS:PPCB) announced its quarterly earnings results on Thursday, May, 15th. The company reported ($12.50) earnings per share for the quarter.

When did Propanc Biopharma's stock split?

Propanc Biopharma shares reverse split before market open on Tuesday, May 23rd 2023.The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

How do I buy shares of Propanc Biopharma?

Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Propanc Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Propanc Biopharma investors own include T2 Biosystems (TTOO), AppYea (APYP), Avis Budget Group (CAR), PayPal (PYPL), Synthetic Biologics (SYN), Corbus Pharmaceuticals (CRBP) and Delcath Systems (DCTH).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/08/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:PPCB
• CIK: 1517681
• Web: www.propanc.com
• Phone: (139) 882-0780
• Fax: 61 03 9882 9969
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.82 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -3,652.66%
• Return on Assets: -971.09%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 2.24
• Quick Ratio: 2.24

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($493.34) per share
• Price / Book: -0.01

Miscellaneous

• Outstanding Shares: 20,000
• Free Float: 19,000
• Market Cap: $132 thousand
• Optionable: Not Optionable
• Beta: 2.52